Cargando…
Prognostic significance of cytoplasmic S100A2 overexpression in oral cancer patients
BACKGROUND: Oral squamous cell carcinoma (OSCC) patients are at high risk of loco-regional recurrence and 5-year survival rates are about 50%. Identification of patients at high risk of recurrence will enable rigorous personalized post-treatment management. Most novel biomarkers have failed translat...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324434/ https://www.ncbi.nlm.nih.gov/pubmed/25591983 http://dx.doi.org/10.1186/s12967-014-0369-9 |
_version_ | 1782356685379076096 |
---|---|
author | Kumar, Manish Srivastava, Gunjan Kaur, Jatinder Assi, Jasmeet Alyass, Akram Leong, Iona MacMillan, Christina Witterick, Ian Shukla, Nootan Kumar Thakar, Alok Duggal, Ritu Roychoudhury, Ajoy Sharma, Mehar Chand Walfish, Paul G Chauhan, Shyam Singh Ralhan, Ranju |
author_facet | Kumar, Manish Srivastava, Gunjan Kaur, Jatinder Assi, Jasmeet Alyass, Akram Leong, Iona MacMillan, Christina Witterick, Ian Shukla, Nootan Kumar Thakar, Alok Duggal, Ritu Roychoudhury, Ajoy Sharma, Mehar Chand Walfish, Paul G Chauhan, Shyam Singh Ralhan, Ranju |
author_sort | Kumar, Manish |
collection | PubMed |
description | BACKGROUND: Oral squamous cell carcinoma (OSCC) patients are at high risk of loco-regional recurrence and 5-year survival rates are about 50%. Identification of patients at high risk of recurrence will enable rigorous personalized post-treatment management. Most novel biomarkers have failed translation for clinical use because of their limited successful validation in external patient cohorts. The aim of this study was to determine the prognostic significance of alterations in sub-cellular expression of S100A2, a pro-tumorigenic calcium binding protein, identified as a candidate biomarker in our proteomic analysis in OSCC and validation of its clinical utility in an external cohort. METHODS: In a retrospective study, immunohistochemical analysis of S100A2 was carried out in 235 Indian OSCC (Test set) and 129 normal oral tissues, correlated with clinicopathological parameters and disease outcome over 122 months for OSCC patients following the REMARK criteria. The findings were validated in an external cohort (Validation set 115 Canadian OSCC and 51 normal tissues) and data analyzed using the R package. RESULTS: Significant increase in cytoplasmic and decrease in nuclear S100A2 expression was observed in OSCC in comparison with normal tissues. Cox multivariable regression analysis internally and externally validated cytoplasmic S100A2 association with tumor recurrence. Kaplan Meier analysis of patients stratified to high and low risk groups showed significantly different recurrence free survival (Test set- log rank test, p = 0.005, median survival 16 and 69 months respectively and Validation set - p < 0.00001, median survival 9.4 and 59.9 months respectively); 86% and 81% of patients who had recurrence were correctly stratified into the high risk group. Seventy percent and 81% patients stratified into low risk group did not show cancer recurrence within 1 year in Test and Validation sets. CONCLUSIONS: Our study provided clinical evidence for the potential of cytoplasmic S100A2 overexpression as a predictor of recurrence risk in OSCC patients. A unique translational aspect of our study is validation of S100A2 as prognostic marker in two independent cohorts (Canadian and Indian) suggesting this protein is likely to find widespread utility in clinical practice for identifying oral cancer patients at high risk of disease recurrence. |
format | Online Article Text |
id | pubmed-4324434 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-43244342015-02-12 Prognostic significance of cytoplasmic S100A2 overexpression in oral cancer patients Kumar, Manish Srivastava, Gunjan Kaur, Jatinder Assi, Jasmeet Alyass, Akram Leong, Iona MacMillan, Christina Witterick, Ian Shukla, Nootan Kumar Thakar, Alok Duggal, Ritu Roychoudhury, Ajoy Sharma, Mehar Chand Walfish, Paul G Chauhan, Shyam Singh Ralhan, Ranju J Transl Med Research BACKGROUND: Oral squamous cell carcinoma (OSCC) patients are at high risk of loco-regional recurrence and 5-year survival rates are about 50%. Identification of patients at high risk of recurrence will enable rigorous personalized post-treatment management. Most novel biomarkers have failed translation for clinical use because of their limited successful validation in external patient cohorts. The aim of this study was to determine the prognostic significance of alterations in sub-cellular expression of S100A2, a pro-tumorigenic calcium binding protein, identified as a candidate biomarker in our proteomic analysis in OSCC and validation of its clinical utility in an external cohort. METHODS: In a retrospective study, immunohistochemical analysis of S100A2 was carried out in 235 Indian OSCC (Test set) and 129 normal oral tissues, correlated with clinicopathological parameters and disease outcome over 122 months for OSCC patients following the REMARK criteria. The findings were validated in an external cohort (Validation set 115 Canadian OSCC and 51 normal tissues) and data analyzed using the R package. RESULTS: Significant increase in cytoplasmic and decrease in nuclear S100A2 expression was observed in OSCC in comparison with normal tissues. Cox multivariable regression analysis internally and externally validated cytoplasmic S100A2 association with tumor recurrence. Kaplan Meier analysis of patients stratified to high and low risk groups showed significantly different recurrence free survival (Test set- log rank test, p = 0.005, median survival 16 and 69 months respectively and Validation set - p < 0.00001, median survival 9.4 and 59.9 months respectively); 86% and 81% of patients who had recurrence were correctly stratified into the high risk group. Seventy percent and 81% patients stratified into low risk group did not show cancer recurrence within 1 year in Test and Validation sets. CONCLUSIONS: Our study provided clinical evidence for the potential of cytoplasmic S100A2 overexpression as a predictor of recurrence risk in OSCC patients. A unique translational aspect of our study is validation of S100A2 as prognostic marker in two independent cohorts (Canadian and Indian) suggesting this protein is likely to find widespread utility in clinical practice for identifying oral cancer patients at high risk of disease recurrence. BioMed Central 2015-01-16 /pmc/articles/PMC4324434/ /pubmed/25591983 http://dx.doi.org/10.1186/s12967-014-0369-9 Text en © Kumar et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Kumar, Manish Srivastava, Gunjan Kaur, Jatinder Assi, Jasmeet Alyass, Akram Leong, Iona MacMillan, Christina Witterick, Ian Shukla, Nootan Kumar Thakar, Alok Duggal, Ritu Roychoudhury, Ajoy Sharma, Mehar Chand Walfish, Paul G Chauhan, Shyam Singh Ralhan, Ranju Prognostic significance of cytoplasmic S100A2 overexpression in oral cancer patients |
title | Prognostic significance of cytoplasmic S100A2 overexpression in oral cancer patients |
title_full | Prognostic significance of cytoplasmic S100A2 overexpression in oral cancer patients |
title_fullStr | Prognostic significance of cytoplasmic S100A2 overexpression in oral cancer patients |
title_full_unstemmed | Prognostic significance of cytoplasmic S100A2 overexpression in oral cancer patients |
title_short | Prognostic significance of cytoplasmic S100A2 overexpression in oral cancer patients |
title_sort | prognostic significance of cytoplasmic s100a2 overexpression in oral cancer patients |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324434/ https://www.ncbi.nlm.nih.gov/pubmed/25591983 http://dx.doi.org/10.1186/s12967-014-0369-9 |
work_keys_str_mv | AT kumarmanish prognosticsignificanceofcytoplasmics100a2overexpressioninoralcancerpatients AT srivastavagunjan prognosticsignificanceofcytoplasmics100a2overexpressioninoralcancerpatients AT kaurjatinder prognosticsignificanceofcytoplasmics100a2overexpressioninoralcancerpatients AT assijasmeet prognosticsignificanceofcytoplasmics100a2overexpressioninoralcancerpatients AT alyassakram prognosticsignificanceofcytoplasmics100a2overexpressioninoralcancerpatients AT leongiona prognosticsignificanceofcytoplasmics100a2overexpressioninoralcancerpatients AT macmillanchristina prognosticsignificanceofcytoplasmics100a2overexpressioninoralcancerpatients AT witterickian prognosticsignificanceofcytoplasmics100a2overexpressioninoralcancerpatients AT shuklanootankumar prognosticsignificanceofcytoplasmics100a2overexpressioninoralcancerpatients AT thakaralok prognosticsignificanceofcytoplasmics100a2overexpressioninoralcancerpatients AT duggalritu prognosticsignificanceofcytoplasmics100a2overexpressioninoralcancerpatients AT roychoudhuryajoy prognosticsignificanceofcytoplasmics100a2overexpressioninoralcancerpatients AT sharmameharchand prognosticsignificanceofcytoplasmics100a2overexpressioninoralcancerpatients AT walfishpaulg prognosticsignificanceofcytoplasmics100a2overexpressioninoralcancerpatients AT chauhanshyamsingh prognosticsignificanceofcytoplasmics100a2overexpressioninoralcancerpatients AT ralhanranju prognosticsignificanceofcytoplasmics100a2overexpressioninoralcancerpatients |